Empowering new drug companies

82VS is our affiliated venture studio that pairs Alloy’s platforms and services with a team of company creation experts to efficiently launch new asset-centric companies. Alloy works with exceptional founders, entrepreneurs- and executives-in-residence, and biotech and pharma partners to develop new medicines by efficiently leveraging the capabilities of the Alloy ecosystem at large.

82VS: Our Venture Studio

We Discover

We are a venture studio leveraging Alloy’s pre-competitive drug discovery platforms. Established drug discovery, scientific, and lab resources allow entrepreneurs to start their first experiment on day one.

We Partner

We partner with academics, entrepreneurs, target-rich companies, pharma, and VC. We lead with our drug discovery work, helping others advance targets of interest.

We Build

We build asset-focused companies while continuing to incorporate new modalities and drug discovery platforms accessible throughout the Alloy ecosystem. Alloy creates new platforms and services on demand to support individual new companies if needed.

We Industrialize

We industrialize repeatable company launch processes across legal, HR, finance, operations, and marketing to minimize startup time and allow scientists to focus on the science. 

Our People

We come from pharma, biotech, academia, and venture capital backgrounds. Our EIRs can pursue their scientific ideas with full operational support and can repeatedly harness the 82VS infrastructure to create more value.

Chris Pacheco Alloy Therapeutics Team

General Partner


Venture Partner


Venture Associate


Director of Bioinformatics

Hemanta Baruah Alloy Therapeutics Team

EIR, Founder and CEO Aakha Biologics

Ben Chih Alloy Therapeutics Team

EIR, Founder and CEO Restoration Biosciences


ExIR, Founder and CEO Aldebaran Therapeutics


EIR, Translational Medicine


Advisor, Founder and CEO Broadwing Bio

Sudhir Agrawal Alloy Therapeutics Team

Chair, Alloy Genetic Medicine Platform Technologies SAB


“82VS is an exciting place to build innovative companies and establish collaborations, making novel drug discovery platforms accessible to innovators and drug developers.”

Sudhir Agrawal, Chair of Alloy Genetic Medicines SAB

Sudhir Agrawal Alloy Therapeutics Team

We launch new companies and support strategic investments

Collectively the companies supported out of 82VS are pursuing next generation innovative treatments for cancer, neurodegeneration, autoimmune disease, hereditary blindness, and more. Our investments in next-generation manufacturing companies help our ecosystem of partners advance more quickly to the clinic.

Option #1 Original




Option #2 Portfolio (Custom Post Type System)

Aakha Biologics discovers and develops biologics to create life-saving therapies for cancer patients.
Aldebaran Therapeutics is advancing medicines for genetic ocular disease.
Broadwing Bio is developing antibody therapies for the leading causes of adult vision loss.
Leviathan Therapeutics is developing bi-and multi-specific biologic therapies to regulate immunometabolism for the treatment of cancers.
Mytide Therapeutics is transforming peptide manufacturing with predictive analytics and machine learning.
Restoration Biosciences is advancing novel genetic medicines for the treatment of neurodegeneration.
Vernal Biosciences is a manufacturer of high purity mRNA for research and clinical use.
Voxall Therapeutics is developing immune-modulating antibodies for novel targets in cancer and autoimmune disease.
Wheeler Bio is democratizing access to rapid, high-quality biomanufacturing with its Portable CMC™ platform.
Ypsilon Therapeutics is developing T cell receptor mimics (TCRm) against validated tumor antigens for the treatment of cancers.

Collaboration is in our name


The 82VS name comes from the atomic number for lead, 82. To us, lead represents the most boring of metals that can form alloys, frequently used in low-cost solder to bring other metals together. This is because we seek to be behind the scenes and to fade into the background as we let our entrepreneurs and their companies take the credit for their great work.


We create, in-license, and co-develop pre-competitive enabling technology platforms that help the entire drug discovery community move faster.

We value the work of inventors, ensuring your work lands with maximum impact. There is nothing more frustrating to a scientist or engineer than to see their life’s work trapped inside one company and only able to be accessed and improved by a single team. Alloy’s mission is to unlock the potential of pre-competitive technologies by taking a very long view of investing in platform development and helping our partners and venture studios utilize these technologies as aggressively as possible. Generally, platform technology continues to be improved over time and with greater use and engagement from the ecosystem. It’s exciting to think that the technologies we invent today will be supported, improved and available to our ecosystem today and long into the future.  Alloy reinvests 100% of our revenue back into innovation and access to innovation while sharing the value with the innovators themselves.
Have a pre-competitive technology to share?
Accept Privacy Settings Here
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please read and Privacy Policy
Consent to display content from Youtube
Consent to display content from Vimeo
Google Maps
Consent to display content from Google
Consent to display content from Spotify
Sound Cloud
Consent to display content from Sound